PORT WASHINGTON, N.Y., June 14, 2010 -
New Brunswick Scientific, an Eppendorf Company (Edison, NJ, www.nbsc.com),
and Pall Corporation (Port Washington, NY, www.pall.com)
today announced a joint product development and marketing agreement to
create and supply new disposable bioreactor systems.
The joint effort will build on the capabilities of Pall’s Allegro™
single-use biocontainer platform and New Brunswick’s CelliGen®
bioprocess controller, to better serve upstream applications ranging
from the process development laboratory to the full-scale cGMP
This partnership combines the historic market strengths of the two
companies in upstream biopharmaceutical processing, strengths that have
been recently augmented by New Brunswick Scientific’s development of the
CelliGen BLU Single-Use Stirred-Tank Bioreactor, and Pall’s acquisition
of MicroReactor Technologies and the Micro-24 microbioreactor.
According to Mike Sattan, New Brunswick’s Vice President Marketing,
“This is an exciting step forward, as the new system will enable us to
offer an even broader range of bioreactor technology options, while we
continue to provide a control system with the reliability, ease of use
and configurability that our customers have come to expect.”
Ken Frank, President Pall Life Sciences Biopharmaceuticals, said, “We
are delighted to be able to partner with New Brunswick to extend our
Allegro single-use technology to cover the entire range of upstream
bioprocessing applications. We believe these new bioreactor systems will
provide our customers with greater benefits in operational simplicity,
product quality assurance, and process economics.”
About New Brunswick Scientific
New Brunswick Scientific’s (NBS) headquarters is based in Edison, N.J.
USA, with sales and distributor offices located worldwide. Founded in
1946, NBS is a leading manufacturer of innovative equipment for culture
growth, detection and storage. The company offers a broad range of cell
culture bioreactors, including stirred-tank and packed-bed bioreactors
in 1 – 3,000 liter capacities, as well as their new single-use
bioreactor, the CelliGen BLU, introduced earlier this year. Biological
shakers, fermentors, CO2 incubators and ultra-low temperature
freezers round out their product line.
About Pall Corporation
Pall Corporation (NYSE: PLL) is a filtration, separation and
purification leader providing Total Fluid ManagementSM
solutions to meet the critical needs of customers in biopharmaceutical;
hospital, transfusion and veterinary medicine; energy and alternative
energy; electronics; municipal and industrial water; aerospace;
transportation and broad industrial markets. Together with our
customers, we foster health, safety and environmentally responsible
technologies. The company’s engineered solutions enable process and
product innovation and minimize emissions and waste. Pall Corporation,
with total revenues of $2.3 billion for fiscal 2009, is an S&P 500
company with more than 10,000 employees serving customers worldwide.
Pall has been named a top "green company" by Newsweek magazine.
To see how Pall is helping enable a greener, safer, more sustainable
future, visit www.pall.com/green.
Pall Life Sciences Carol Flint, 734-913-6432 Global V.P.
Marketing Communications firstname.lastname@example.org